Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.
Learn about:
- Association between ApoM and heart failure outcomes
- Effects of the chemotherapeutic drug doxorubicin on ApoM levels
- How ApoM heterozygosity affects the regulation of transcription factor EB
Ali Javaheri, MD
Assistant Professor, Medicine, Cardiovascular Division
Washington University School of Medicine in St. Louis
Ali Javaheri, MD, is Assistant Professor of Medicine and Investigator in the Center for Cardiovascular Research at Washington University in St. Louis, and broadly trained in multiple disciplines. His clinical expertise and training is in advanced heart failure, a syndrome with no cure that has a worse prognosis than many cancers (5 year 50% mortality). He has led and contributed to studies that have utilized proteomic strategies to uncover the importance of novel pathways in human heart failure. These studies have highlighted the important role of apolipoprotein M (ApoM). Reduced circulating ApoM is associated with poor prognosis in heart failure. Dr. Javaheri shows the ApoM-content of isolated high-density lipoprotein correlates strongly with its sphingosine-1-phosphate content; however, adjusting for sphingosine-1-phosphate levels only partially attenuated the association between ApoM and heart failure survival. Together with Dr. Mahmoud Nasr at Harvard Medical School, Dr. Javaheri recently filed a provisional patent for nanotherapies related to ApoM. His ongoing studies on ApoM suggest significant translational potential for this pathway in heart failure.
Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
A presentation by Ali Javaheri, MD
More webinars
WebinarBoutique Webinar Aptamers with protein-like side chains as a versatile tool for high-content proteomics
Proteins, encoded in 20,000 genes in humans, do much of the work in biology. Measuring proteins, which change in response to various perturbations and represent targets for almost all drugs, offers insights about the health status of an organism. Since proteins operate in complex networks rather than in isolation, measuring multiple proteins simultaneously offers richer insights compared to single protein measurements.
WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.
WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies
High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.